Migraine Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The migraine market size has grown steadily in recent years. It will grow from $1.93 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 2.2%. The growth in the historic period can be attributed to increasing prevalence of migraines, growing awareness about migraine treatment, government initiatives, increasing prevalence of alcohol consumption, shifts in lifestyle.

The migraine market size is expected to see steady growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to adoption of combination therapies, growing number of screening programs for migraines, increasing prevalence of smoking habits, awareness of the importance of lifestyle management for migraine. Major trends in the forecast period include innovative treatments for migraines, development of targeted therapies for migraines, advancements in diagnosis and treatment of migraines, digital health technologies for migraine management.

The growing prevalence of migraines is poised to fuel the expansion of the migraine market in the foreseeable future. Migraines are severe headaches typically affecting one side of the head, characterized by intense throbbing pain or a pulsing sensation. Migraine treatments offer several advantages, including pain relief, improved functionality, reduced frequency and severity of attacks, enhanced productivity, and a better quality of life for individuals grappling with migraines. For instance, in January 2023, as reported by Nature Reviews Neurology, a UK-based journal website, the current global estimate indicates a migraine prevalence of 14-15%, contributing to 4.9% of the total global years lived with disability (YLDs). Hence, the increasing prevalence of migraines is a key driver of the migraine market's growth.

The increasing prevalence of stress is the driving force behind the growth of the migraine market. Stress represents the physiological and psychological response to challenging or demanding situations that individuals perceive as threatening, overwhelming, or beyond their ability to cope with effectively. Stress can act as a trigger for migraines, as it initiates the body's fight or flight response, leading to the release of stress hormones like cortisol and adrenaline. These hormones can induce rapid constriction and dilation of blood vessels, potentially contributing to changes in blood flow and vascular function associated with migraine attacks. For example, data from the American Psychiatric Association, a US-based professional organization of psychiatrists, indicated that over one in four (26%) Americans anticipated experiencing increased stress at the beginning of 2023, up from one in five (20%) the previous year. Consequently, the rising incidence of stress is fueling the expansion of the migraine market.

The prominent companies in the migraine market are dedicated to pioneering technological solutions like migraine lens technology to gain a competitive advantage. Migraine lens technology entails the development of specialized lenses tailored to alleviate discomfort in individuals with migraines and sensitivity to light. For example, in July 2023, Zenni Optical Inc., a US-based eyewear retailer, unveiled its groundbreaking innovation, the FL-41 migraine lenses. These lenses are engineered to provide relief to individuals suffering from light sensitivity due to migraines, post-concussion recovery, and other related conditions. Moreover, these lenses filter out a specific range of light that is known to trigger eye pain, thereby reducing the risk of migraines and even offering relief during active migraine episodes.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for an estimated $11.6 billion. This strategic acquisition is part of Pfizer's efforts to enhance its portfolio and further its commitment to providing innovative treatment options for individuals suffering from migraines. Biohaven Pharmaceuticals Inc. is a US-based pharmaceutical company renowned for its development of migraine medications.

Major companies operating in the migraine market are Pfizer Inc., Johnson and Johnson Limited, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Limited, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Lannett Company Inc., Wockhardt Limited.

North America was the largest region in the migraine market in 2024. The regions covered in migraine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the migraine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The migraine market consists of revenues earned by entities by providing transcranial magnetic stimulation (TMS), relaxation therapies, stress management therapies, cognitive therapies and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The migraine market also includes sales of prescription and over-the-counter (OTC) drugs, medical devices and alternative therapies for the treatment of migraines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A migraine is a neurological disorder characterized by recurrent and intense headaches, often accompanied by additional symptoms like nausea, vomiting, sensitivity to light (photophobia), and sensitivity to sound (phonophobia). These headaches are typically one-sided, pulsating, and can persist for several hours to a few days. The management of migraines involves a combination of strategies aimed at providing relief from immediate symptoms during an attack and preventing future migraine episodes.

Migraines come in two primary types are episodic and chronic. Chronic migraine is defined as experiencing headaches on at least 15 days per month for a minimum of three months, with at least 8 days each month featuring migraine-like symptoms. Treatment options include both preventive and abortive measures, involving various drug classes such as triptans, ergots, and others.

The migraine market research report is one of a series of new reports that provides migraine market statistics, including the migraine industry global market size, regional shares, competitors with a migraine market share, detailed migraine market segments, market trends and opportunities and any further data you may need to thrive in the migraine industry. This migraine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.